Conversion of Ouabain-Induced Ventricular Tachycardia in Dogs with Epicardial Lidocaine: Pharmacodynamics and Functional Effects
dc.contributor.author | Scott, William A. | en_US |
dc.contributor.author | Levy, Robert J. | en_US |
dc.contributor.author | Sintov, Amnon | en_US |
dc.contributor.author | Gallagher, Kim P. | en_US |
dc.date.accessioned | 2006-09-08T19:22:04Z | |
dc.date.available | 2006-09-08T19:22:04Z | |
dc.date.issued | 1990-01 | en_US |
dc.identifier.citation | Sintov, Amnon; Scott, William A.; Gallagher, Kim P.; Levy, Robert J.; (1990). "Conversion of Ouabain-Induced Ventricular Tachycardia in Dogs with Epicardial Lidocaine: Pharmacodynamics and Functional Effects." Pharmaceutical Research 7(1): 28-33. <http://hdl.handle.net/2027.42/41538> | en_US |
dc.identifier.issn | 0724-8741 | en_US |
dc.identifier.issn | 1573-904X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/41538 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2300532&dopt=citation | en_US |
dc.description.abstract | Epicardial antiarrhythmic drug administration was studied as a therapeutic approach for experimental ventricular tachycardia (VT) in an open-chest dog model. Lidocaine-polyurethane matrices (28%, w/w) were formulated as a model system. Matrices were placed on the left ventricular epicardium in each of 23 anesthetized open-chest dogs with ouabain-induced VT, to evaluate effectiveness in restoring sinus rhythm. Conversion occurred in all animals treated with matrices containing 300 mg or more of lidocaine after 1.5 to 7.0 min. The matrix lidocaine content correlated linearly with the time required for conversion to sinus rhythm ( r = 0.75, P = 0.0002); irrespective of matrix size the myocardial/plasma lidocaine ratio was 20.1 ± 4.2 (mean ± SD) at the time of conversion. In a separate series of five dogs without ventricular tachycardia, systolic wall thickening measured with sonomicrometers after 5 min of controlled-release lidocaine administration (500- to 1000-mg matrix lidocaine content, 7.48 ± 3.49-mg/kg dose) was only minimally diminished (−14.1%) and this effect was observed only at the site of matrix placement on the anterior-apical epicardium. In contrast, intracoronary injection of 0.3 or 1.0 mg/kg of lidocaine-HCl resulted in complete elimination of wall thickening or replacement by systolic thinning. Thus epicardial administration of lidocaine from polyurethane matrices was an effective means of treating ouabain-induced ventricular tachycardia. Regional myocardial function in the vicinity of the matrices was modified to a very limited degree, supporting the view that the matrices can be used safely, without serious risk to ventricular contractile performance. | en_US |
dc.format.extent | 1106442 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Controlled Release | en_US |
dc.subject.other | Pharmacy | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Biomedical Engineering | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Lidocaine | en_US |
dc.subject.other | Medical Law | en_US |
dc.subject.other | Arrhythmia | en_US |
dc.subject.other | Ventricular Tachycardia | en_US |
dc.title | Conversion of Ouabain-Induced Ventricular Tachycardia in Dogs with Epicardial Lidocaine: Pharmacodynamics and Functional Effects | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pediatrics, C. S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, Michigan, 48109; Department of Pharmaceutics, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109 | en_US |
dc.contributor.affiliationum | Department of Pediatrics, C. S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, Michigan, 48109 | en_US |
dc.contributor.affiliationum | Department of Pediatrics, C. S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, Michigan, 48109; Department of Pharmaceutics, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109; Kresge II, Room 5080, The University of Michigan, Box 0576, Ann Arbor, Michigan, 48109-0576 | en_US |
dc.contributor.affiliationum | Departments of Physiology and Surgery, University of Michigan Medical School, Ann Arbor, Michigan, 48109 | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 2300532 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/41538/1/11095_2004_Article_305656.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1015875223446 | en_US |
dc.identifier.source | Pharmaceutical Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.